CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
NCT07351643
Summary
The aim of this clinical trial is to investigate whether dapagliflozin (a sodium-glucose cotransporter 2 inhibitor, SGLT2i) can reduce levels of coronary inflammation in patients with stage 4 CKM syndrome. Coronary inflammation will be measured using the fat attenuation index (FAI), a marker derived from coronary CT angiography (CCTA) that quantifies inflammation in the fat tissue surrounding heart arteries. The main questions it aims to answer are * Does dapagliflozin lower coronary artery inflammation as measured by FAI? * Does dapagliflozin slow the progression of coronary plaques? Researchers will compare participants who take dapagliflozin 10 mg daily plus standard therapy to those who receive standard therapy alone for 6 months. Participants will: * Undergo percutaneous coronary intervention (PCI) for ACS * Have a baseline CCTA scan at 1 month after PCI, at which point they will be randomly assigned to receive dapagliflozin or standard care alone. * Have a follow-up CCTA scan at 6 months after randomisation. * Receive follow-up phone calls at 3 and 6 months after randomisation
Eligibility
Inclusion Criteria 1. Aged ≥ 18 years, irrespective of gender; 2. Meeting the diagnostic criteria for stage 4 CKM syndrome; 3. Able to cooperate with photon-counting CT examination during the index hospitalisation, with no contraindications to the examination; 4. Signed informed consent form. Exclusion Criteria 1. Receiving SGLT2 inhibitor therapy within 4 weeks prior to enrolment; 2. Severe hepatic dysfunction (Child-Pugh class C); 3. History of recurrent urogenital tract infections; 4. History of allergy or intolerance to SGLT2 inhibitors; 5. Pregnant or lactating women; 6. Systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 60 mmHg; 7. Severe chronic kidney disease (eGFR \< 30 mL/min/1.73 m²); 8. Participation in other interventional clinical trials; 9. Other conditions deemed inappropriate for enrolment by the investigator(s).
Conditions3
Interventions1
Related trials
- "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial" — Beni-Suef University
- CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL — 4th Military Clinical Hospital with Polyclinic, Poland
- Dapagliflozin in Depression — Tanta University
- Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes — University of Sao Paulo
- SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes — The George Institute
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus — AstraZeneca
- A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus — AstraZeneca
- Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) — Washington University School of Medicine
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07351643